ISSN: 1472-8214

Journal Home

Journal Guideline

Expert Opinion on Emerging Drugs Q1 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Expert Opinion on Emerging Drugs is a journal indexed in SJR in Pharmacology and Pharmacology (medical) with an H index of 54. It has a price of 4000 €. It has an SJR impact factor of 0,881 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 0,881.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Pharmacology (medical) (Q1) Pharmacology (medical) (Q1) Pharmacology (Q2)

Price

4000 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,881

SJR Impact factor

54

H Index

29

Total Docs (Last Year)

110

Total Docs (3 years)

2695

Total Refs

321

Total Cites (3 years)

102

Citable Docs (3 years)

2.62

Cites/Doc (2 years)

92.93

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Pharmacological Reviews Q1
Drug Resistance Updates Q1
Annual Review of Pharmacology and Toxicology Q1
Molecular Therapy Q1
Journal for ImmunoTherapy of Cancer Q1

Compare this journals

Aims and Scope

Best articles by citations

Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation

The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies

Bisphosphonate therapy in the oncology setting

Emerging oral drugs for psoriasis

Emerging oral drugs for relapsing-remitting multiple sclerosis

Current and emerging therapies for the lysosomal storage disorders

Advances in pharmacotherapy for tobacco dependence

Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention

Fusion/entry inhibitors as therapies for HIV

Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective

Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia

Emerging reverse transcriptase inhibitors for HIV-1 infection

SHOW MORE ARTICLES

Emerging analgesics in cancer pain management

Emerging angiogenesis inhibitors for non-small cell lung cancer

Antithrombotic agents in the treatment of severe sepsis

Histone modification enzymes: novel targets for cancer drugs

Prospects and problems of gene therapy: an update

Pharmacological agents in development for invasive aspergillosis

ADP receptor antagonists as antiplatelet therapeutics

Emerging azole antifungals

The development of erythropoietic agents in oncology

Emerging drug for diarrhea predominant irritable bowel syndrome

Emerging drug treatments for cystic fibrosis

Emerging drugs for acute and chronic heart failure: current and future developments